Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
3.1 Cohort Characteristics In total, 526 medicinal products were authorised between 1 July 2012, and 31 December 2021. Approximately one-quarter (n = 132, 25.1%) of those were authorised with at least one aRMM tool (Supplementary Fig. S2). Among these 132 medicinal products with at least one aRMM tool, the majority were granted standard MA (84.1%) and remained authorised at the end of follow-up (84.8%; Table 2).
Drug Safety, Sep 2023 In studies evaluating the effectiveness of additional risk minimisation measures (aRMMs), the need for speed must be properly balanced with the quality of the study. We assessed the duration of aRMM effectiveness evaluations, using additional pharmacovigilance activities, for centrally authorised medicinal products in the European Union.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.